

Allison W Kurian

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5351490/allison-w-kurian-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

280

papers

8,586

citations

53

h-index

87

g-index

318

ext. papers

11,095

ext. citations

5.5

avg, IF

6.11

L-index

#	Paper	IF	Citations
280	Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. <i>PLoS ONE</i> , 2012 , 7, e33788	3.7	415
279	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2001-9	2.2	363
278	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 9-20	7.3	319
277	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. <i>JAMA Oncology</i> , 2015 , 1, 943-51	13.4	226
276	Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 2374-84	27.4	201
275	Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. <i>Journal of Clinical Oncology</i> , 2010 , 28, 222-31	2.2	189
274	Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 902-14	27.4	178
273	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 380-391	7.3	171
272	Genetic/familial high-risk assessment: breast and ovarian. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 562-94	7.3	169
271	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1895-901	2.2	166
270	Differences in Breast Cancer Survival by Molecular Subtypes in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 619-626	4	164
269	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1094-101	9.7	157
268	Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2232-2239	2.2	150
267	Occurrence of breast cancer subtypes in adolescent and young adult women. <i>Breast Cancer Research</i> , 2012 , 14, R55	8.3	134
266	A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 533-44	5.1	133
265	CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. <i>Annals of Surgery</i> , 2007 , 245, 873-9	7.8	133
264	Histologic types of epithelial ovarian cancer: have they different risk factors?. <i>Gynecologic Oncology</i> , 2005 , 96, 520-30	4.9	132

263	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 77-102	7.3	131
262	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 154-164	27.4	130
261	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010 , 22, 72-8	2.4	129
260	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1305-1315	2.2	126
259	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 153-62	7.3	123
258	Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 471-8	4.4	118
257	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. <i>Breast Cancer Research</i> , 2010 , 12, R99	8.3	117
256	A Population-Based Study of Genes Previously Implicated in Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 440-451	59.2	115
255	Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky062	4.6	102
254	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1326-38	7.3	101
253	A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 634-41	2.2	100
252	Biomedical terahertz imaging with a quantum cascade laser. <i>Applied Physics Letters</i> , 2006 , 88, 153903	3.4	98
251	Second primary breast cancer occurrence according to hormone receptor status. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1058-65	9.7	90
250	Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. <i>JAMA Oncology</i> , 2018 , 4, 1066-1072	13.4	87
249	Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. <i>JAMA Surgery</i> , 2017 , 152, 274-282	5.4	84
248	The California breast density information group: a collaborative response to the issues of breast density, breast cancer risk, and breast density notification legislation. <i>Radiology</i> , 2013 , 269, 887-92	20.5	80
247	Trends in Reoperation After Initial Lumpectomy for Breast Cancer: Addressing Overtreatment in Surgical Management. <i>JAMA Oncology</i> , 2017 , 3, 1352-1357	13.4	79
246	Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 531-534	27.4	78

245	Obesity and mortality after breast cancer by race/ethnicity: The California Breast Cancer Survivorship Consortium. <i>American Journal of Epidemiology</i> , 2014 , 179, 95-111	3.8	75
244	Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. <i>PLoS ONE</i> , 2012 , 7, e43994	3.7	74
243	Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1039-45	4	73
242	A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2594-8	3.1	73
241	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. <i>Genetics in Medicine</i> , 2018 , 20, 234-239	8.1	72
240	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. <i>Cancer</i> , 2004 , 100, 479-89	6.4	70
239	Online tool to guide decisions for BRCA1/2 mutation carriers. <i>Journal of Clinical Oncology</i> , 2012 , 30, 497-506	5.6	69
238	Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1584-91	2.2	66
237	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016 , 115, 129-35	8.7	64
236	Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Radiology</i> , 2018 , 288, 26-35	20.5	63
235	Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. <i>Cancer</i> , 2018 , 124, 3668-3676	6.4	59
234	Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. <i>Radiology</i> , 2017 , 285, 401-413	20.5	59
233	Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. <i>Journal of Medical Genetics</i> , 2016 , 53, 15-23	5.8	57
232	Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways. <i>Clinical Cancer Research</i> , 2017 , 23, 3334-3342	12.9	54
231	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2008 , 7, 179-86	3	54
230	Multigene Panel Testing in Oncology Practice: How Should We Respond?. <i>JAMA Oncology</i> , 2015 , 1, 277-81	13.4	53
229	Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 361-8	4	53
228	Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 1084-91	4	53

227	Performance of BRCA1/2 mutation prediction models in Asian Americans. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4752-8	2.2	52
226	Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. <i>Journal of Clinical Oncology</i> , 2010 , 28, e155-7; author reply e158	2.2	48
225	Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 95-98	9.7	47
224	Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-12	3.6	45
223	Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1218-1224	2.2	43
222	The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. <i>Cancer Causes and Control</i> , 2013 , 24, 1821-36	2.8	41
221	Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. <i>Journal of Community Health</i> , 2015 , 40, 1287-99	4	40
220	Tumor Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. <i>Clinical Cancer Research</i> , 2017 , 23, 3365-3370	12.9	39
219	Treatment decisions and employment of breast cancer patients: Results of a population-based survey. <i>Cancer</i> , 2017 , 123, 4791-4799	6.4	39
218	Breast Cancer Risk Reduction, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 880-915	7.3	39
217	Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research. <i>Cancer</i> , 2014 , 120, 103-11	6.4	39
216	Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 493-500	9.7	38
215	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 2851-2858	12.9	38
214	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. <i>JAMA Network Open</i> , 2020 , 3, e208501	10.4	38
213	Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. <i>American Journal of Public Health</i> , 2015 , 105, 938-46	5.1	37
212	A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1066-77	4	37
211	Recurrence risk perception and quality of life following treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 557-565	4.4	35
210	Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. <i>Cancer</i> , 2017 , 123, 1925-1934	6.4	34

209	Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. <i>Cancer Causes and Control</i> , 2016 , 27, 1127-38	2.8	34
208	Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 247-60	4.4	32
207	Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4505-9	2.2	32
206	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. <i>Nature Communications</i> , 2020 , 11, 3833	17.4	31
205	Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. <i>Medical Decision Making</i> , 2018 , 38, 9S-23S	2.5	29
204	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015 , 27, 23-33	2.4	28
203	Genetic insights into biological mechanisms governing human ovarian ageing. <i>Nature</i> , 2021 , 596, 393-397	50.4	28
202	Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 219-228	7.3	27
201	Contribution of the neighborhood environment and obesity to breast cancer survival: the California Breast Cancer Survivorship Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1282-90	4.0	25
200	Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. <i>JAMA Network Open</i> , 2020 , 3, e2019452	10.4	25
199	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>JAMA Oncology</i> , 2020 , 6, 1218-1230	13.4	25
198	Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 997-8	27.4	24
197	Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. <i>Cancer Research</i> , 2018 , 78, 4241-4252	10.1	24
196	A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 389-98	4.4	24
195	The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 525-535	4.4	23
194	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1484-1494	9.7	22
193	The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 27	5.4	21
192	Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. <i>Familial Cancer</i> , 2012 , 11, 429-39	3	21

191	Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-12	5.2	21
190	Patient communication of cancer genetic test results in a diverse population. <i>Translational Behavioral Medicine</i> , 2018 , 8, 85-94	3.2	21
189	Linking electronic health records to better understand breast cancer patient pathways within and between two health systems. <i>EGEMS (Washington, DC)</i> , 2015 , 3, 1127	2.2	20
188	Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1082-9	4	20
187	How can we best respect patient autonomy in breast cancer treatment decisions?. <i>Breast Cancer Management</i> , 2015 , 4, 53-64	0.7	19
186	The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1064-72	4	19
185	Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research 2012 , 2012, 970-8	0.7	18
184	Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences. <i>JAMA Oncology</i> , 2017 , 3, 391-397	13.4	17
183	Beyond barriers: fundamental 'disconnects' underlying the treatment of breast cancer patients' sexual health. <i>Culture, Health and Sexuality</i> , 2014 , 16, 1169-80	2.5	17
182	Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. <i>World Journal of Surgery</i> , 2012 , 36, 702-13	3.3	17
181	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. <i>Health Expectations</i> , 2005 , 8, 221-33	3.7	17
180	Genetics of triple-negative breast cancer: Implications for patient care. <i>Current Problems in Cancer</i> , 2016 , 40, 130-140	2.3	17
179	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 1332-1341	4	17
178	Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. <i>JAMA Surgery</i> , 2018 , 153, 909-916	5.4	17
177	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	16
176	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. <i>Nature Communications</i> , 2020 , 11, 1217	17.4	16
175	Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer. <i>Cancer</i> , 2017 , 123, 43-51	6.4	16
174	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated () Gene are Associated with High and Moderate Risks for Multiple Cancers. <i>Cancer Prevention Research</i> , 2021 , 14, 433-440	3.2	16

173	History of Recreational Physical Activity and Survival After Breast Cancer: The California Breast Cancer Survivorship Consortium. <i>American Journal of Epidemiology</i> , 2015 , 181, 944-55	3.8	15
172	Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. <i>Breast Cancer Research</i> , 2015 , 17, 108	8.3	15
171	The decline in breast cancer incidence: real or imaginary?. <i>Current Oncology Reports</i> , 2009 , 11, 21-8	6.3	15
170	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1631-1640	2.2	15
169	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, 44-56	7.1	15
168	Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 995-997	27.4	14
167	Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. <i>JAMIA Open</i> , 2019 , 2, 528-537	2.9	14
166	A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2013 , 2, 95-103 ²	2.2	14
165	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 329-337	9.7	14
164	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 931-3	4.4	13
163	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. <i>Value in Health</i> , 2018 , 21, 1062-1068	3.3	12
162	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 36, 44-56	7.1	12
161	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020 , 107, 837-848	11	12
160	Validation of self-reported comorbidity status of breast cancer patients with medical records: the California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Causes and Control</i> , 2016 , 27, 391-401 ^{2.8}	2.8	12
159	Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 895-902	4	11
158	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2020 , 6, e196400	13.4	11
157	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 72	6	11
156	Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. <i>Current Breast Cancer Reports</i> , 2009 , 1, 148-156	0.8	11

155	Patient, hospital, and neighborhood factors associated with treatment of early-stage breast cancer among Asian American women in California. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 821-34	4	11
154	Tobacco Smoking and Risk of Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 968-979	9	11
153	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2007 , 179, 89-92		10
152	Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. <i>Journal of Oncology Practice</i> , 2016 , 12, e697-709	3.1	10
151	Dynamic strategy for personalized medicine: An application to metastatic breast cancer. <i>Journal of Biomedical Informatics</i> , 2017 , 68, 50-57	10.2	9
150	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. <i>EBioMedicine</i> , 2019 , 48, 203-211	8.8	9
149	Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2018 , 143, 3262-3272	7.5	9
148	Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012. <i>Annals of Surgery</i> , 2017 , 266, 353-360	7.8	9
147	Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1069-1069	2.2	9
146	The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 587-595	4.4	8
145	Primary care provider-reported involvement in breast cancer treatment decisions. <i>Cancer</i> , 2019 , 125, 1815-1822	6.4	8
144	Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 1237-1245	4	8
143	Genomic landscape of ductal carcinoma in situ and association with progression. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 307-316	4.4	8
142	Patient-clinician interactions and disparities in breast cancer care: the equality in breast cancer care study. <i>Journal of Cancer Survivorship</i> , 2019 , 13, 968-980	5.1	8
141	Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks. <i>American Journal of Clinical Pathology</i> , 2017 , 148, 199-207	1.9	8
140	Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2013 , 12, 65-73	3	8
139	Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. <i>Cancer</i> , 2019 , 125, 943-951	6.4	8
138	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	8

137	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	7
136	Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 751-756	4.4	7
135	Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 662-668	7.3	7
134	Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. <i>JCO Oncology Practice</i> , 2020 , 16, e37-e55	2.3	7
133	Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. <i>Cancer</i> , 2020 , 126, 958-970	6.4	7
132	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. <i>Cancer</i> , 2021 , 127, 1275-1285	6.4	7
131	Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. <i>Value in Health</i> , 2020 , 23, 551-558	3.3	6
130	What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?. <i>Medical Decision Making</i> , 2018 , 38, 95-106	2.5	6
129	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3918-3926	2.2	6
128	Automatic inference of BI-RADS final assessment categories from narrative mammography report findings. <i>Journal of Biomedical Informatics</i> , 2019 , 92, 103137	10.2	6
127	Rapid detection of recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. <i>Oncotarget</i> , 2018 , 9, 7832-7843	3.3	6
126	The Impact of COVID-19 on Patients With Cancer: A National Study of Patient Experiences. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 580-587	2.7	6
125	Precision Medicine in Breast Cancer Care: An Early Glimpse of Impact. <i>JAMA Oncology</i> , 2015 , 1, 1109-10	13.4	5
124	Information technology interventions to improve cancer care quality: a report from the American Society of Clinical Oncology Quality Care Symposium. <i>Journal of Oncology Practice</i> , 2013 , 9, 142-4	3.1	5
123	High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 605-7	4.4	5
122	Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. <i>Breast Journal</i> , 2007 , 13, 281-6	1.2	5
121	Comparing 5-Year and Lifetime Risks of Breast Cancer Using the Prospective Family Study Cohort. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 785-791	9.7	5
120	Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. <i>JAMA Oncology</i> , 2021 , 7, 585-592	13.4	5

119	Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. <i>Cancer Medicine</i> , 2021 , 10, 1012-1017	4.8	5
118	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.. <i>JAMA Oncology</i> , 2022 ,	13.4	5
117	Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies. <i>PLoS ONE</i> , 2018 , 13, e0195666	3.7	4
116	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
115	Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	4
114	Navigating choices when applying multiple imputation in the presence of multi-level categorical interaction effects. <i>Statistical Methodology</i> , 2015 , 27, 82-99		3
113	Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology. <i>Breast Journal</i> , 2008 , 14, 211-4	1.2	3
112	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
111	Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer. <i>JCO Oncology Practice</i> , 2021 , 17, e1837-e1845	2.3	3
110	Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial. <i>Cancer</i> , 2018 , 124, 4000-4009	6.4	3
109	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2893-2902	2.2	3
108	Synergistic drug combinations from electronic health records and gene expression. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017 , 24, 565-576	8.6	2
107	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz062	4.6	2
106	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020 , 10, 9688	4.9	2
105	Health Disparities in Germline Genetic Testing for Cancer Susceptibility. <i>Current Breast Cancer Reports</i> , 2020 , 12, 51-58	0.8	2
104	A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 512-7	7.3	2
103	Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 560-560	2.2	2
102	Performance of the IBIS/Tyrer-Cuzick (TC) Model by race/ethnicity in the Women's Health Initiative.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1503-1503	2.2	2

101	Multiple imputation with missing data indicators. <i>Statistical Methods in Medical Research</i> , 2021 , 30, 2685-2700	2	
100	Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 351-363	4	2
99	Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1506-1506	2.2	2
98	Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 469-478	5.2	2
97	Weakly supervised temporal model for prediction of breast cancer distant recurrence. <i>Scientific Reports</i> , 2021 , 11, 9461	4.9	2
96	Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
95	Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. <i>Journal of Genetic Counseling</i> , 2021 ,	2.5	2
94	Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988-2013. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 333-338	4.4	2
93	Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 1173-1185	2.1	2
92	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021 , 124, 842-854	8.7	2
91	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. <i>JCO Precision Oncology</i> , 2018 , 2, 1-10	3.6	2
90	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. <i>Cancer</i> , 2021 , 127, 3742-3750	6.4	2
89	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1479-1489	8.9	2
88	Polygenic risk scores for prediction of breast cancer risk in Asian populations.. <i>Genetics in Medicine</i> , 2021 ,	8.1	2
87	Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. <i>British Journal of Cancer</i> , 2017 , 116, e2	8.7	1
86	Hospital Characteristics and Breast Cancer Survival in the California Breast Cancer Survivorship Consortium. <i>JCO Oncology Practice</i> , 2020 , 16, e517-e528	2.3	1
85	Chromatin Remodeling in Response to BRCA2-Crisis. <i>Cell Reports</i> , 2019 , 28, 2182-2193.e6	10.6	1
84	Multiple-Gene Panels and the Future of Genetic Testing. <i>Current Breast Cancer Reports</i> , 2015 , 7, 98-104	0.8	1

83	Genetic Polymorphisms as Predictors of Breast Cancer Risk. <i>Current Breast Cancer Reports</i> , 2012 , 4, 232-239	2.2	1
82	Reply to D.G. Evans et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1143-1144	2.2	1
81	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1513-1513	2.2	1
80	Genetic testing decisions of breast cancer patients: Results from the iCanCare study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1541-1541	2.2	1
79	Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1503-1503	2.2	1
78	Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5510-5510	2.2	1
77	Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1528-1528	2.2	1
76	Unmet need for clinician engagement about financial toxicity after diagnosis of breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10080-10080	2.2	1
75	Computing the cost of care per day of breast cancer survivor care.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10-10	2.2	1
74	Preventive surgery after multiplex genetic panel testing (MGPT).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1525-1525	2.2	1
73	Oncotype DX DCIS use and clinical utility: A SEER population-based study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12046-e12046	2.2	1
72	Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2043-2043	2.2	1
71	Gaps in integrating genetic testing into management of breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 160-160	2.2	1
70	Patterns of social media use and associations with psychosocial outcomes among breast and gynecologic cancer survivors. <i>Journal of Cancer Survivorship</i> , 2021 , 15, 677-684	5.1	1
69	Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care. <i>JCO Oncology Practice</i> , 2021 , 17, e1403-e1412	2.3	1
68	Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 600-614	5.2	1
67	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021 , 108, 1190-1203	11	1
66	Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1788	13.4	1

65	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021 , 23, 86	8.3	1
64	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics.. <i>Cancer Medicine</i> , 2021 ,	4.8	1
63	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.. <i>Breast Cancer Research</i> , 2022 , 24, 27	8.3	1
62	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. <i>Cancers</i> , 2022 , 14, 2716	6.6	1
61	A case of a trans-masculine patient receiving testosterone with a history of estrogen receptor-positive breast cancer. <i>Breast Journal</i> , 2020 , 26, 1888-1889	1.2	0
60	Rare germline copy number variants (CNVs) and breast cancer risk.. <i>Communications Biology</i> , 2022 , 5, 65	6.7	0
59	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021 , 11, 19787	4.9	0
58	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6531-6531	2.2	0
57	Receipt of guideline-concordant care among young adult women with breast cancer. <i>Cancer</i> , 2021 , 127, 3325-3333	6.4	0
56	Addressing inherited predisposition for breast cancer in transplant recipients. <i>Journal of Surgical Oncology</i> , 2016 , 113, 605-8	2.8	0
55	Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa083	4.6	0
54	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021 , 125, 1135-1145	8.7	0
53	Development of a Mobile Health App (TOGETHERCare) to Reduce Cancer Care Partner Burden: Product Design Study. <i>JMIR Formative Research</i> , 2021 , 5, e22608	2.5	0
52	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab090	4.6	0
51	Response to Peshkin, Isaacs, and Schwartz. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 874	9.7	
50	Reply to S.M. Sorscher and A.B. Hafeez Bhatti. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4233	2.2	
49	Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy. <i>Cancer</i> , 2020 , 126, 2317-2318	6.4	
48	Trends in germline genetic testing and results into survivorship for women diagnosed with breast cancer or ovarian cancer, 2013 to 2017.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 273-273	2.2	

47	Reply to Ritzwoller et al. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 1026-1027	5.2
46	Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1582-1582	2.2
45	Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1578-1578	2.2
44	Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1581-1581	2.2
43	Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women's Health Initiative.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1513-1513	2.2
42	Radiomics features to identify distinct subtypes of triple-negative breast cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3069-3069	2.2
41	Differences among Asian/Asian American, and Caucasian breast and gynecologic cancer patient-reported survivorship needs, symptoms, and illness mindsets (N=220).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11620-11620	2.2
40	Adherence to breast cancer treatment guidelines according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 34-34	2.2
39	Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 7063-7063	2.2
38	Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1504-1504	2.2
37	Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1549-1549	2.2
36	Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19314-e19314	2.2
35	Use of the 21-gene recurrence score assay (RS) and chemotherapy (CT) across health care (HC) systems.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6580-6580	2.2
34	Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 565-565	2.2
33	Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing (CHMT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17515-e17515	2.2
32	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients: Knowledge and physician influence.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1011-1011	2.2
31	Prevalence and consequences of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6508-6508	2.2
30	Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 185-185	2.2

- 29 Recurrence risk perception and quality of life after treatment of breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, 175-175 2.2
- 28 Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients.. *Journal of Clinical Oncology*, **2016**, 34, 177-177 2.2
- 27 Breast oncology precision medicine: Genomic testing and treatment at the population level.. *Journal of Clinical Oncology*, **2016**, 34, 288-288 2.2
- 26 Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. *Journal of Clinical Oncology*, **2016**, 34, 1010-1010 2.2
- 25 Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay.. *Journal of Clinical Oncology*, **2016**, 34, 6552-6552 2.2
- 24 Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012.. *Journal of Clinical Oncology*, **2016**, 34, 1052-1052 2.2
- 23 Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, 6501-6501 2.2
- 22 Yield of multiplex panel testing compared to expert opinion and validated prediction models.. *Journal of Clinical Oncology*, **2016**, 34, 1509-1509 2.2
- 21 Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.. *Journal of Clinical Oncology*, **2016**, 34, 1512-1512 2.2
- 20 Dissemination of 21-gene assay testing among female breast cancer patients in the US.. *Journal of Clinical Oncology*, **2016**, 34, 6553-6553 2.2
- 19 Recent time trends in chemotherapy use and oncologists' chemotherapy recommendations for early-stage, hormone receptor-positive breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, 541-541 2.2
- 18 Factors associated with 21-gene assay receipt among women with lymph node positive breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, 6554-6554 2.2
- 17 Treatment decisions and employment of breast cancer patients: Results of a population-based survey.. *Journal of Clinical Oncology*, **2017**, 35, 10052-10052 2.2
- 16 Expanded yield of multiplex panel testing in fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1525-1525 2.2
- 15 Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.. *Journal of Clinical Oncology*, **2017**, 35, 1523-1523 2.2
- 14 Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1576-1576 2.2
- 13 Identification and Management of Women at High Familial Risk for Breast Cancer **2010**, 135-145
- 12 Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply. *JAMA - Journal of the American Medical Association*, **2020**, 324, 397-398 27.4

- 11 Multicancer hereditary syndrome testing: Genetic counselors' perspectives.. *Journal of Clinical Oncology*, **2021**, 39, 10594-10594 2.2
- 10 Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 10517-10517 2.2
- 9 Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.. *Journal of Clinical Oncology*, **2021**, 39, 10531-10531 2.2
- 8 Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: Estimates from collaborative simulation modeling.. *Journal of Clinical Oncology*, **2021**, 39, 6562-6562 2.2
- 7 Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.. *Journal of Clinical Oncology*, **2021**, 39, 10500-10500 2.2
- 6 A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions?. *Journal of Clinical Oncology*, **2021**, 39, e12507-e12507 2.2
- 5 Guidelines Do Not Proscribe Surgeons Performing Genetic Testing-Reply. *JAMA Surgery*, **2019**, 154, 269-270 3.4
- 4 Multicancer hereditary syndrome testing: Genetic counselors' perspectives.. *Journal of Clinical Oncology*, **2021**, 39, 106-106 2.2
- 3 Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model. *Cancer Research*, **2022**, 82, P2-11-21-P2-11-21 10.1
- 2 Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016.. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, 379-386.e9 7.3
- 1 Relevance of the MHC region for breast cancer susceptibility in Asians.. *Breast Cancer*, **2022**, 1 3.4